# Histopathology Following CCH Injection

> **NCT04236635** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Characteristics of Subcutaneous Tissue

## Interventions

- **DRUG:** Collagenase Clostridium Histolyticum Single Injection Technique
- **DRUG:** Collagenase Clostridium Histolyticum Multiple Injection Technique

## Key facts

- **NCT ID:** NCT04236635
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-10-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236635, "Histopathology Following CCH Injection". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04236635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*